4569 KYORIN Pharmaceutical Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4569

TSE Prime

KYORIN Pharmaceutical Co.,Ltd.

1,482

JPY

+13

(+0.88%)

Dec 5, 1:27 pm JST

9.57

USD

Dec 4, 11:27 pm EST

Result

PTS

outside of trading hours

1,481.8

Dec 5, 1:10 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	105,534	5,007	5,569	3,932	68.6	52	May 11, 2022	J-GAAP
Mar, 2023	113,270	5,123	5,827	4,723	82.4	52	May 11, 2023	J-GAAP
Mar, 2024	119,532	6,234	6,822	5,475	95.4	52	May 10, 2024	J-GAAP
Mar, 2025	130,087	12,567	13,219	9,086	158.2	57	May 12, 2025	J-GAAP
Mar, 2026 Guidance	127,000	6,100	6,300	4,800	83.6	57	May 12, 2025	J-GAAP
YoY	-2.4%	-51.5%	-52.3%	-47.2%	-47.2%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 12, 2020	115,500	9,700	10,200	7,600	75	J-GAAP
	Nov 5, 2020	108,000	7,800	8,400	7,200	75	J-GAAP
	May 7, 2021	102,900	5,700	6,400	6,100	75	J-GAAP
Results	May 11, 2021	102,904	5,786	6,447	6,130	75	J-GAAP
Mar, 2022	May 11, 2021	Available in future release
	Apr 26, 2022
Results	May 11, 2022
Mar, 2023	May 11, 2022
Results	May 11, 2023
Mar, 2024	May 11, 2023
Results	May 10, 2024
Mar, 2025	May 10, 2024
	Apr 23, 2025
Results	May 12, 2025
Mar, 2026	May 12, 2025	127,000	6,100	6,300	4,800	57	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	55,832	+5.8	Available in future release
Mar, 2002	62,395	+11.8
Mar, 2003	68,618	+10.0
Mar, 2004	65,061	-5.2
Mar, 2005	66,296	+1.9
Mar, 2006	74,054	+11.7
Mar, 2007	77,093	+4.1
Mar, 2008	81,070	+5.2
Mar, 2009	90,889	+12.1
Mar, 2010	99,764	+9.8
Mar, 2011	104,069	+4.3
Mar, 2012	103,232	-0.8
Mar, 2013	107,031	+3.7
Mar, 2014	111,400	+4.1
Mar, 2015	113,121	+1.5
Mar, 2016	119,483	+5.6
Mar, 2017	115,373	-3.4
Mar, 2018	110,640	-4.1
Mar, 2019	113,620	+2.7
Mar, 2020	109,983	-3.2
Mar, 2021	102,904	-6.4
Mar, 2022	105,534	+2.6
Mar, 2023	113,270	+7.3
Mar, 2024	119,532	+5.5
Mar, 2025	130,087	+8.8
Mar, 2026 Guidance	127,000	-2.4	6,100	-51.5	6,300	-52.3	83.6	-47.2

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	119,532	6,234	5.22	4.27	3.10	0.68	95.4
Mar, 2025	130,087	12,567	9.66	6.81	4.89	0.70	158.2
Mar, 2026 Guidance	127,000	6,100	4.80	3.52	2.58	0.68	83.6

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	130,087	19,636	19,995	13,639	184.3
Fiscal Year	Mar, 2025	Mar, 2016	Mar, 2016	Mar, 2016	Mar, 2016

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	64,177	4,346	4,656	3,481	60.8	32	May 11, 2023	J-GAAP
Oct - Mar, 2023	64,595	4,899	5,244	3,585	62.5	32	May 10, 2024	J-GAAP
Oct - Mar, 2024	74,948	11,018	11,169	7,831	136.3	37	May 12, 2025	J-GAAP
Oct - Mar, 2025 Guidance	68,269	4,737	4,718	3,306	57.6	37	Nov 7, 2025	J-GAAP
YoY	-8.9%	-57.0%	-57.8%	-57.8%	-57.8%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	5,123	-4,267	2,008	-6,275	-3,363	18,816	10.69	J-GAAP
Mar, 2024	6,234	-1,638	1,549	-3,187	-3,347	13,886	7.82	J-GAAP
Mar, 2025	12,567	-2,817	3,506	-6,323	3,952	15,021	7.76	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	54,937	1,335	1,578	1,890	33.0	23.1	Nov 8, 2023	J-GAAP
Apr - Sep, 2024	55,139	1,549	2,050	1,255	21.9	15.5	Nov 7, 2024	J-GAAP
Apr - Sep, 2025	58,731	1,363	1,582	1,494	26.0	25.1	Nov 7, 2025	J-GAAP
YoY	+6.5%	-12.0%	-22.8%	+19.0%	+19.0%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	32,330	3,468	3,813	2,259	39.4	10.7	Feb 6, 2024	J-GAAP
Jan - Mar, 2024	32,265	1,431	1,431	1,326	23.1	4.4	May 10, 2024	J-GAAP
Apr - Jun, 2024	28,419	1,150	1,417	885	15.4	4.0	Jul 31, 2024	J-GAAP
Jul - Sep, 2024	26,720	399	633	370	6.4	1.5	Nov 7, 2024	J-GAAP
Oct - Dec, 2024	34,147	1,566	1,703	1,184	20.6	4.6	Feb 5, 2025	J-GAAP
Jan - Mar, 2025	40,801	9,452	9,466	6,647	115.7	23.2	May 12, 2025	J-GAAP
Apr - Jun, 2025	30,229	2,368	2,624	2,100	36.6	7.8	Jul 31, 2025	J-GAAP
Jul - Sep, 2025	28,502	-1,005	-1,042	-606	-10.6	-3.5	Nov 7, 2025	J-GAAP
YoY	+6.7%	－	－	－	－

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	27,220	-10.2	Available in future release
Jan - Mar, 2021	27,949	-10.9
Apr - Jun, 2021	24,695	0.0
Jul - Sep, 2021	24,407	+5.9
Oct - Dec, 2021	28,615	+5.1
Jan - Mar, 2022	27,817	-0.5
Apr - Jun, 2022	24,619	-0.3
Jul - Sep, 2022	24,474	+0.3
Oct - Dec, 2022	31,614	+10.5
Jan - Mar, 2023	32,563	+17.1
Apr - Jun, 2023	27,854	+13.1
Jul - Sep, 2023	27,083	+10.7
Oct - Dec, 2023	32,330	+2.3
Jan - Mar, 2024	32,265	-0.9
Apr - Jun, 2024	28,419	+2.0
Jul - Sep, 2024	26,720	-1.3
Oct - Dec, 2024	34,147	+5.6
Jan - Mar, 2025	40,801	+26.5
Apr - Jun, 2025	30,229	+6.4
Jul - Sep, 2025	28,502	+6.7	-1,005	－	-1,042	－	-10.6	－

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	40,801	10,567	10,680	7,864	115.7
Fiscal Year	Mar, 2025	Dec, 2015	Dec, 2015	Dec, 2015	Mar, 2025

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	2,189.40	71.3	176,045	125,461	134,396	0.17	May 11, 2023	J-GAAP
Mar, 2024	2,275.68	73.6	177,627	130,735	136,726	0.16	May 10, 2024	J-GAAP
Mar, 2025	2,372.29	70.4	193,618	136,285	142,789	0.20	May 12, 2025	J-GAAP
Apr - Sep, 2025	ー	73.4	186,013	136,448	130,711	0.16	Nov 7, 2025	J-GAAP

KYORIN Pharmaceutical Co.,Ltd.(4569) Financial Results